1887

Abstract

Hantaan virus (HTNV), a member of the family , is a major agent causing haemorrhagic fever with renal syndrome, a high-mortality-rate disease threatening approximately 150 000 people around the world yearly. The 3D8 mAb displays a neutralizing activity to HTNV infection. In this study, the B-cell epitopes of HTNV glycoproteins (GPs) were finely mapped by peptide scanning. A new B-cell epitope GFLCPEFPGSFRKKC of HTNV, which locates on Gc, has been screened out from a set of 15-mer synthesized peptides covering the full-length of HTNV-GPs. It has been shown by the alanine-scanning technique that C, R, K, K and C are the key amino acids of the binding sites of the GPs. The implications of identifying a novel B-cell epitope for hantavirus immunology and vaccinology are discussed.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.045302-0
2012-12-01
2020-04-07
Loading full text...

Full text loading...

/deliver/fulltext/jgv/93/12/2595.html?itemId=/content/journal/jgv/10.1099/vir.0.045302-0&mimeType=html&fmt=ahah

References

  1. Antoniades A., Grekas D., Rossi C. A., LeDuc J. W. 1987; Isolation of a hantavirus from a severely ill patient with hemorrhagic fever with renal syndrome in Greece. J Infect Dis 156:1010–1013 [CrossRef][PubMed]
    [Google Scholar]
  2. Arikawa J., Schmaljohn A. L., Dalrymple J. M., Schmaljohn C. S. 1989; Characterization of Hantaan virus envelope glycoprotein antigenic determinants defined by monoclonal antibodies. J Gen Virol 70:615–624 [CrossRef][PubMed]
    [Google Scholar]
  3. Arikawa J., Yao J. S., Yoshimatsu K., Takashima I., Hashimoto N. 1992; Protective role of antigenic sites on the envelope protein of Hantaan virus defined by monoclonal antibodies. Arch Virol 126:271–281 [CrossRef][PubMed]
    [Google Scholar]
  4. Bui-Mansfield L. T., Cressler D. K. 2011; Imaging of hemorrhagic fever with renal syndrome: a potential bioterrorism agent of military significance. Mil Med 176:1327–1334[PubMed] [CrossRef]
    [Google Scholar]
  5. de Carvalho Nicacio C., Lundkvist A., Sjölander K. B., Plyusnin A., Salonen E. M., Björling E. 2000; A neutralizing recombinant human antibody Fab fragment against Puumala hantavirus. J Med Virol 60:446–454 [CrossRef][PubMed]
    [Google Scholar]
  6. Dowling W., Thompson E., Badger C., Mellquist J. L., Garrison A. R., Smith J. M., Paragas J., Hogan R. J., Schmaljohn C. 2007; Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of Ebola virus GP DNA vaccines. J Virol 81:1821–1837 [CrossRef][PubMed]
    [Google Scholar]
  7. Gnann J. W. Jr, Nelson J. A., Oldstone M. B. 1987; Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. J Virol 61:2639–2641[PubMed]
    [Google Scholar]
  8. Huggins J. W., Hsiang C. M., Cosgriff T. M., Guang M. Y., Smith J. I., Wu Z. O., LeDuc J. W., Zheng Z. M., Meegan J. M. other authors 1991; Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 164:1119–1127 [CrossRef][PubMed]
    [Google Scholar]
  9. Jonsson C. B., Figueiredo L. T., Vapalahti O. 2010; A global perspective on hantavirus ecology, epidemiology, and disease. Clin Microbiol Rev 23:412–441 [CrossRef][PubMed]
    [Google Scholar]
  10. Kikuchi M., Yoshimatsu K., Arikawa J., Yoshida R., Yoo Y. C., Isegawa Y., Yamanishi K., Tono-oka S., Azuma I. 1998; Characterization of neutralizing monoclonal antibody escape mutants of Hantaan virus 76118. Arch Virol 143:73–83 [CrossRef][PubMed]
    [Google Scholar]
  11. Koch J., Liang M., Queitsch I., Kraus A. A., Bautz E. K. 2003; Human recombinant neutralizing antibodies against Hantaan virus G2 protein. Virology 308:64–73 [CrossRef][PubMed]
    [Google Scholar]
  12. Koivunen E., Gay D. A., Ruoslahti E. 1993; Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. J Biol Chem 268:20205–20210[PubMed]
    [Google Scholar]
  13. Koivunen E., Wang B., Ruoslahti E. 1994; Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library. J Cell Biol 124:373–380 [CrossRef][PubMed]
    [Google Scholar]
  14. Liang M., Mahler M., Koch J., Ji Y., Li D., Schmaljohn C., Bautz E. K. 2003; Generation of an HFRS patient-derived neutralizing recombinant antibody to Hantaan virus G1 protein and definition of the neutralizing domain. J Med Virol 69:99–107 [CrossRef][PubMed]
    [Google Scholar]
  15. X., Yin W., Yang Q., Lei Y., Yang J., Sun M., Yao M., Xu Z., Xue X. 2009; Identification of oligopeptides mimicking the receptor-binding domain of Hantaan virus envelope glycoprotein from a phage-displayed peptide library. Can J Microbiol 55:664–671 [CrossRef][PubMed]
    [Google Scholar]
  16. Lundkvist A., Björsten S., Niklasson B., Ahlborg N. 1995; Mapping of B-cell determinants in the nucleocapsid protein of Puumala virus: definition of epitopes specific for acute immunoglobulin G recognition in humans. Clin Diagn Lab Immunol 2:82–86[PubMed]
    [Google Scholar]
  17. McCaughey C., Hart C. A. 2000; Hantaviruses. J Med Microbiol 49:587–599[PubMed]
    [Google Scholar]
  18. Peters C. J., Simpson G. L., Levy H. 1999; Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Annu Rev Med 50:531–545 [CrossRef][PubMed]
    [Google Scholar]
  19. Rusnak J. M., Byrne W. R., Chung K. N., Gibbs P. H., Kim T. T., Boudreau E. F., Cosgriff T., Pittman P., Kim K. Y. other authors 2009; Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea. Antiviral Res 81:68–76 [CrossRef][PubMed]
    [Google Scholar]
  20. Safronetz D., Haddock E., Feldmann F., Ebihara H., Feldmann H. 2011; In vitro and in vivo activity of ribavirin against Andes virus infection. PLoS ONE 6:e23560 [CrossRef][PubMed]
    [Google Scholar]
  21. Tischler N. D., Galeno H., Rosemblatt M., Valenzuela P. D. 2005; Human and rodent humoral immune responses to Andes virus structural proteins. Virology 334:319–326 [CrossRef][PubMed]
    [Google Scholar]
  22. Xu Z. 2011; Research and applications of monoclonal antibodies in viral disease therapy. Chin J Viral Dis 1:401–404
    [Google Scholar]
  23. Xu Z., Wei L., Wang L., Wang H., Jiang S. 2002; The in vitro and in vivo protective activity of monoclonal antibodies directed against Hantaan virus: potential application for immunotherapy and passive immunization. Biochem Biophys Res Commun 298:552–558 [CrossRef][PubMed]
    [Google Scholar]
  24. Xu R., Yang X. Y., Yang D. F., Zou C. Y., Gong P. L., Zeng F. D. 2009; Phase I evaluation of the safety and pharmacokinetics of a single-dose intravenous injection of a murine monoclonal antibody against Hantaan virus in healthy volunteers. Antimicrob Agents Chemother 53:5055–5059 [CrossRef][PubMed]
    [Google Scholar]
  25. Yoshimatsu K., Arikawa J., Tamura M., Yoshida R., Lundkvist A., Niklasson B., Kariwa H., Azuma I. 1996; Characterization of the nucleocapsid protein of Hantaan virus strain 76-118 using monoclonal antibodies. J Gen Virol 77:695–704 [CrossRef][PubMed]
    [Google Scholar]
  26. Zhu Z., Dimitrov A. S., Chakraborti S., Dimitrova D., Xiao X., Broder C. C., Dimitrov D. S. 2006; Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses. Expert Rev Anti Infect Ther 4:57–66 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.045302-0
Loading
/content/journal/jgv/10.1099/vir.0.045302-0
Loading

Data & Media loading...

Most cited this month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error